These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 28831550

  • 1. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    Lattanzi S, Danni M, Taffi R, Cerqua R, Carlini G, Pulcini A, Provinciali L, Silvestrini M.
    J Neurol; 2017 Nov; 264(11):2325-2329. PubMed ID: 28831550
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M.
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [Abstract] [Full Text] [Related]

  • 3. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A, NTD Study Group.
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [Abstract] [Full Text] [Related]

  • 6. Real-life use of oral disease-modifying treatments in Austria.
    Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [Abstract] [Full Text] [Related]

  • 7. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.
    J Neurol Sci; 2019 Dec 15; 407():116498. PubMed ID: 31644992
    [Abstract] [Full Text] [Related]

  • 8. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).
    J Neurol; 2020 Jul 15; 267(7):2090-2100. PubMed ID: 32246251
    [Abstract] [Full Text] [Related]

  • 9. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.
    J Neurol Neurosurg Psychiatry; 2019 Apr 15; 90(4):458-468. PubMed ID: 30636699
    [Abstract] [Full Text] [Related]

  • 10. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y, SFSEP and OFSEP groups.
    Neurology; 2019 Aug 13; 93(7):e635-e646. PubMed ID: 31300547
    [Abstract] [Full Text] [Related]

  • 11. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B, Pellkofer H, Weber MS.
    Curr Neurol Neurosci Rep; 2016 Apr 13; 16(4):38. PubMed ID: 26944956
    [Abstract] [Full Text] [Related]

  • 12. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
    Duquette P, Yeung M, Mouallif S, Nakhaipour HR, Haddad P, Schecter R.
    PLoS One; 2019 Apr 13; 14(1):e0210417. PubMed ID: 30640935
    [Abstract] [Full Text] [Related]

  • 13. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

  • 14. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.
    Mult Scler Relat Disord; 2016 Nov 01; 10():204-212. PubMed ID: 27919491
    [Abstract] [Full Text] [Related]

  • 15. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C, Bramanti P, Mazzon E.
    Drug Des Devel Ther; 2017 Nov 01; 11():2193-2207. PubMed ID: 28814828
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E.
    Ann Clin Transl Neurol; 2019 Feb 01; 6(2):252-262. PubMed ID: 30847358
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons.
    Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M.
    Ther Adv Neurol Disord; 2024 Feb 01; 17():17562864241237856. PubMed ID: 38855023
    [Abstract] [Full Text] [Related]

  • 18. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
    Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, Evans C, Tremlett H.
    Mult Scler Relat Disord; 2019 Jan 01; 27():364-369. PubMed ID: 30476872
    [Abstract] [Full Text] [Related]

  • 19. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G.
    Adv Ther; 2014 Nov 01; 31(11):1134-54. PubMed ID: 25414048
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
    Bosco-Lévy P, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, Heinzlef O, Lignot S, Diez P, Abouelfath A, Lassalle R, Blin P, Droz-Perroteau C.
    Br J Clin Pharmacol; 2022 Mar 01; 88(3):1268-1278. PubMed ID: 34505304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.